Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Document › Details

Synpromics Ltd.. (8/14/15). "Press Release: Synpromics Announces Fundraise Completion".

Organisations Organisation Synpromics Ltd.
  Group AskBio (Group)
  Organisation 2 Calculus Capital Ltd.
Products Product synthetic biotechnology
  Product 2 private equity
Index terms Index term Synpromics–SEVERAL: investment, 201508 financing round €na incl £2.1m funding from Calculus Capital
  Index term 2 Synpromics–Calculus Capital: investment, 201508 financing round incl £2.1m funding from Calculus Capital
Person Person Venables, David (Synpromics 201508 CEO)

Synpromics announces that it has completed a financing round including £2.1m of new funding from Calculus Capital (“Calculus”). The funds will be used for business expansion and further development of Synpromics’ proprietary synthetic promoter technology.

Commenting, John Brown (chairman), said “Synpromics is a very exciting company working in the highly dynamic synthetic biology industry. The investment recognises the fantastic work of the science team in successfully achieving its technical objectives for all of our projects whilst the business development pipeline has developed significantly, based on the technical success to date. We have a great team and welcome calculus to the company.”

David Venables (CEO) added “we are extremely pleased to have attracted this investment from a leading eis fund that has strong technology expertise. The work done by Michael Roberts (CSO and founder) and his team has evidenced the robustness of the technology and its wide applicability across gene therapy, agroscience, bioprocessing including yeast and mammalian cells. We now plan to focus our growth efforts in particular areas leveraging the great results from our projects. Recent data from a project in cho cells showed a ten fold improvement in yield using custom made promoters whilst other projects have shown that we can achieve highly specific levels of control over gene expression. These results make us a compelling partner for many biotech and synthetic biology businesses. We look forward to building the business with Calculus.”

Alexandra Lindsay (Calculus) added “We are very excited to invest in Synpromics. The highly capable team, comprehensive IP and leading technology, together with Calculus Capital’s support, will ensure Synpromics is primed to take full advantage of the significant market opportunity available."

About Calculus

Calculus Capital is a specialist in creating and managing private equity funds for individuals. A pioneer in the enterprise investment scheme (EIS) space, calculus launched the UK’s first approved EIS fund in 1999 and has gone on to launch 15 further funds. Calculus seeks capital appreciation from dynamic, established, private UK companies across a multitude of sectors, calculus prefers to invest £2m - £5m per company.

Record changed: 2019-08-13


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for AskBio (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top